NASDAQ$DTIL
Precision BioSciences Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Precision BioSciences reported Q1 2025 revenue of $4.5M, a net loss of $18.2M.
For Q1 2025, Precision BioSciences reported Revenue was $4.5M, net loss was $18.2M. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Revenue $4.5M for Q1 2025.
- Net loss $18.2M.
- MD&A highlights operating priorities, liquidity, and sector-specific risks.
Headline financials
Revenue & EPS history
Precision BioSciences · Revenue · Quarterly
$29K
Forward guidance
Clinical-stage outlook focuses on trial readouts, partnerships, and cash runway.
Tailwinds
- Pipeline milestones and collaboration potential.
- Cash resources to fund R&D programs.
Headwinds
- Trial and regulatory risk.
- Operating losses until commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-1.6%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-4.3%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+16.4%
Q3 2020
Best reaction
-20.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | +0.8% | — | |
| Q4 2025 | +12.1% | +37.0% | +31.8% | |
| Q3 2025 | -9.8% | -24.8% | -38.0% | |
| Q1 2025 | -8.1% | -1.4% | -1.0% | |
| Q4 2024 | -11.0% | -6.3% | +4.7% | |
| Q3 2024 | -6.2% | -7.1% | -31.5% | |
| Q2 2024 | -2.2% | -8.7% | +14.2% | |
| Q1 2024 | +9.2% | +16.5% | +10.4% | |
| Q4 2023 | +6.4% | -25.4% | -8.3% | |
| Q3 2023 | -1.8% | -5.3% | +1.2% | |
| Q2 2023 | -1.5% | +0.2% | -9.6% | |
| Q1 2023 | -2.4% | -12.2% | -10.9% | |
| Q4 2022 | -20.9% | -22.7% | -31.3% | |
| Q3 2022 | +6.5% | +18.5% | -6.5% | |
| Q2 2022 | -12.1% | +15.5% | -9.2% | |
| Q1 2022 | -4.1% | -18.0% | -6.2% | |
| Q4 2021 | -14.4% | -7.0% | -42.5% | |
| Q3 2021 | +8.9% | +0.7% | -8.8% | |
| Q2 2021 | -3.2% | -10.9% | +20.9% | |
| Q1 2021 | +6.4% | +6.5% | +29.7% | |
| Q4 2020 | -3.9% | -11.4% | -24.0% | |
| Q3 2020 | +16.4% | +32.5% | +1.8% | |
| Q2 2020 | -7.6% | -9.4% | -21.4% | |
| Q1 2020 | +1.2% | +7.1% | +3.7% | |
| Q4 2019 | -9.7% | -14.0% | -12.4% | |
| Q3 2019 | +11.3% | +42.4% | +14.9% | |
| Q2 2019 | -3.7% | +6.4% | +6.9% | |
| Q1 2019 | +2.8% | -6.0% | +6.5% | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro